LENZ Therapeutics Q4 net loss widens on VIZZ launch costs

LENZ Therapeutics

24/03/2026 12:11

Overview

US pharmaceutical company's Q4 2025 product revenue reached $1.6 mln after VIZZ launch

Net loss for Q4 2025 widened to $35.9 mln, reflecting higher SG&A expenses

Company expanded sales force to support VIZZ demand and prescriber uptake

Outlook

Company expects over 45,000 paid prescriptions for VIZZ from launch through Q1 2026

LENZ is expanding sales force to 117 territories, full deployment expected in Q2 2026

Company continues international regulatory filings and partnerships for VIZZ in Europe and Asia

Result Drivers

PRESCRIBER ADOPTION - Broad uptake by eye care professionals drove initial VIZZ sales, with over 6,500 unique prescribers in Q4 2025 and over 20,000 prescriptions filled

CONSUMER AWARENESS CAMPAIGN - Direct-to-consumer campaign featuring Sarah Jessica Parker increased consumer engagement and website traffic

SALES FORCE EXPANSION - Company expanded sales organization to support growing demand and prescriber base

Company press release: ID:nGNXZhQvL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$35.90 mln
Q4 Income from Operations
-$38.46 mln
Q4 Operating Expenses
$40.05 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for LENZ Therapeutics Inc is $52.00, about 372.7% above its March 23 closing price of $11.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)